By: Rowan Walrath
Vaxart is weeks away from a key readout from its COVID-19 vaccine-pill trial San Diego —The vaccine developer Vaxart is aiming to get back on track after a turbulent year.
Rowan Walrath is a Life Sciences Reporter at various esteemed publications. She covers a range of topics within the realms of science, natural sciences, medicine, and healthcare, with a particular focus on drugs and medication, health news, and digital health. Rowan's work has been featured in the Charlotte Business Journal, NBC Boston, and the American Chemical Society, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Rowan predominantly covers healthcare, pharmaceuticals, and biotechnology. She often reports on company announcements such as acquisitions, FDA approvals, IPO filings, and product developments in the life sciences industry.
To effectively pitch to Rowan Walrath consider offering exclusive insights or expert analysis related to new drug approvals by the FDA, significant mergers or acquisitions within the biotech sector, groundbreaking advancements in medical devices or gene therapy technologies. Additionally, if you are part of a company making major announcements in these areas it could be of interest to her.
While there is no specified geographic focus for Rowan's coverage area she appears to cover national and international news pertaining to healthcare and the pharmaceutical industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .